Novonesis stock (DK0060336014): Kepler Cheuvreux upgrades to Buy

Kepler Cheuvreux has upgraded Novonesis to Buy from Hold, highlighting the company's strong position in biological solutions for food and other industries. The stock trades on Nasdaq Copenhagen.

Novonesis, a leader in biological solutions including enzymes and microbes, received an analyst upgrade from Kepler Cheuvreux to Buy from Hold, as reported on May 14, 2026. The upgrade underscores the firm's potential in replacing chemical processes across industries like food production, according to ad-hoc-news.de as of 05/14/2026. This move reflects optimism about Novonesis' innovation in sustainable biotech.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novonesis A/S
• Sector/industry: Biotechnology / Enzymes
• Headquarters/country: Denmark
• Core markets: Food, agriculture, textiles
• Home exchange/listing venue: Nasdaq Copenhagen (NOVO-B)
• Trading currency: DKK

Novonesis: core business model

Novonesis develops and supplies enzymes, microbes, and biological solutions that enable sustainable processes in industries worldwide. Formed from the merger of Novozymes and Chr. Hansen, the company focuses on replacing traditional chemical methods with biotech alternatives, reducing environmental impact. Its products serve food & beverages, agriculture, and household care sectors, with a strong emphasis on innovation for long-term growth.

The business model relies on R&D investment to create high-performance biological ingredients. Novonesis operates globally, with production sites supporting its supply chain. For US investors, its exposure to the US agriculture and food processing markets provides relevance amid rising demand for sustainable solutions.

Main revenue and product drivers for Novonesis

Food & beverages account for a major revenue share, driven by enzymes for baking, dairy, and brewing. Agriculture products include microbial solutions for animal feed and crop protection. Recent sustainability initiatives, like becoming a bluesign System Partner for textiles, expand its reach into leather and fabric innovation, as noted in industry reports from early 2026.

Key growth drivers include demand for bio-based alternatives in a decarbonizing economy. Novonesis' portfolio benefits from trends in healthspan nutraceuticals and biopesticides, aligning with global shifts toward proactive wellness and sustainable agribusiness.

Industry trends and competitive position

The biotech enzyme market is expanding due to regulatory pressures for greener processes. Novonesis holds a leading position with its broad portfolio and R&D scale. Competitors include DSM and DuPont, but Novonesis differentiates through specialized microbes and enzymes tailored for food safety and efficiency.

Why Novonesis matters for US investors

Listed on Nasdaq Copenhagen, Novonesis offers US investors access to European biotech leadership with significant US market exposure. Its solutions support American agribusiness giants in crop protection and food production, tying into US sustainability goals and farm bill incentives.

Conclusion

The Kepler Cheuvreux upgrade highlights Novonesis' strengths in biological solutions amid sustainability trends. With a solid business in enzymes and microbes, the company is positioned for growth in food and agriculture. US investors may note its relevance to domestic markets, though global economic factors remain influential.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.